GlaxoSmithKline
NEWS
The first week of November was marked by numerous clinical trial announcements. Here’s a look.
GlaxoSmithKline denied reports that they were interested in acquiring Canada’s Aurinia Pharmaceuticals, although some reports claim they are preparing to bid.
Yet another busy week for clinical trial news. Here’s a look.
The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.
Novartis is reviewing its Sandoz division to determine the best moves to maximize value for shareholders. The strategic review will explore all options for the Swiss pharma giant.
Bristol Myers Squibb is reportedly courting Canada’s Aurinia Pharmaceuticals to strike a buyout deal.
Atreca announced it is licensing its preclinical monoclonal antibody for the prevention of malaria to the Gates Medical Research Institute (MRI) for development.
GSK shares are climbing in premarket trading on rumors that the company’s consumer health business it intends to spin off into a separate company next year is attracting interest from venture capitalists.
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
JOBS
IN THE PRESS